Central effects of fexofenadine and cetirizine: Measurement of psychomotor performance, subjective sleepiness, and brain histamine H1-receptor occupancy using 11C-doxepin positron emission tomography

Journal of Clinical Pharmacology

Volumn 44, Issue 8, 2004, Pages 890-900

  Tashiro, Manabu ^a   Sakurada, Yumiko ^a   Iwabuchi, Kentaro ^a   Mochizuki, Hideki ^a   Kato, Motohisa ^a   Aoki, Mariko ^a   Funaki, Yoshihito ^b   Itoh, Masatoshi ^b   Iwata, Ren ^b   Wong, Dean F ^c   Yanai, Kazuhiko ^a,d  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c DEPARTMENT OF PATHOLOGY   (United States)

^d TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Cetirizine; Fexofenadine; H1 receptor occupancy (H1RO); Histamine H1 receptor (H1R); Positron emission tomography (PET); Psychomotor performance; Second generation antihistamine; Sleepiness

Indexed keywords

CARBON 13; CETIRIZINE; DOXEPIN; FEXOFENADINE; PLACEBO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COGNITIVE DEFECT; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG RECEPTOR BINDING; HUMAN; HUMAN EXPERIMENT; ISOTOPE LABELING; MALE; NORMAL HUMAN; POSITRON EMISSION TOMOGRAPHY; PSYCHOMOTOR PERFORMANCE; RANDOMIZED CONTROLLED TRIAL; RATING SCALE; RESPONSE TIME; SOMNOLENCE; STANFORD SLEEPINESS SCALE;

ADULT; BRAIN; CARBON RADIOISOTOPES; CETIRIZINE; CROSS-OVER STUDIES; DOUBLE-BLIND METHOD; DOXEPIN; HISTAMINE H1 ANTAGONISTS; HISTAMINE H1 ANTAGONISTS, NON-SEDATING; HUMANS; MALE; POSITRON-EMISSION TOMOGRAPHY; PRACTICE GUIDELINES; PSYCHOMOTOR PERFORMANCE; RECEPTORS, HISTAMINE H1; SLEEP STAGES; TERFENADINE;

EID: 3242751214     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0091270004267590     Document Type: Article

References (52)

1. Passalacqua G, Scordamaglia A, Ruffoni S, Parodi MN, Canonica GW: Sedation from H1 antagonists: evaluation methods and experimental results. Allergol Immunopathol (Madr) 1993;21(2):79-83.
2. Simons FE: H1-receptor antagonists: comparative tolerability and safety. Drug Saf 1994;10(5):350-380.
3. Adelsberg BR: Sedation and performance issues in the treatment of allergic conditions. Arch Intern Med 1997;157(5):494-500.
4. Mattila MJ, Paakkari I: Variations among non-sedating antihistamines: are there real differences? Eur J Clin Pharmacol 1999;55(2): 85-93.
5. Philpot EE: Safety of second generation antihistamines. Allergy Asthma Proc 2000;21(1):15-20.
6. Mann RD, Pearce GL, Dunn N, Shakir S: Sedation with "non- sedating" antihistamines: four prescription-event monitoring studies in general practice. Br Med J 2000;320:1184-1186.
7. Lee EE, Maibach HI: Treatment of urticaria: an evidence-based evaluation of antihistamines. Am J Clin Dermatol 2001;2(1):27-32.
8. Gandon JM, Allain H: Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. Br J Clin Pharmacol 2002;54(1):51-58.
9. Hindmarch I, Shamsi Z, Kimber S: An evaluation of the effects of high-dose fexofenadine on the central nervous system: a double-blind, placebo-controlled study in healthy volunteers. Clin Exp Allergy 2002;32(1):133-139.
10. Bradley CM, Nicholson AN: Studies on the central effects of the H1-antagonist, loratadine. Eur J Clin Pharmacol 1987;32(4):419-421.
11. Gengo FM, Dabronzo J, Yurchak A, Love S, Miller JK: The relative antihistaminic and psychomotor effects of hydroxyzine and cetirizine. Clin Pharmacol Ther 1987;42(3):265-272.
12. Gengo FM, Gabos C: Antihistamines, drowsiness, and psychomotor impairment: central nervous system effect of cetirizine. Ann Allergy 1987;59(6, Pt. 2):53-57.
13. Doms M, Vanhulle G, Baelde Y, Coulie P, Dupont P, Rihoux JP: Lack of potentiation by cetirizine of alcohol-induced psychomotor disturbances. Eur J Clin Pharmacol 1988;34(6):619-623.
14. Gengo FM, Gabos C, Mechtler L: Quantitative effects of cetirizine and diphenhydramine on mental performance measured using an automobile driving simulator. Ann Allergy 1990;64(6):520-526.
15. Woodward JK: Pharmacology of antihistamines. J Allergy Clin Immunol 1990;86(4, Pt, 2):606-612.
16. Ramaekers JG, Uiterwijk MM, O'Hanlon JF: Effects of loratadine and cetirizine on actual driving and psychometric test performance, and EEG during driving. Eur J Clin Pharmacol 1992;42(4):363-369.
17. Walsh JK, Muehlbach MJ, Schweitzer PK: Simulated assembly line performance following ingestion of cetirizine or hydroxyzine. Ann Allergy 1992;69(3):195-200.
18. Patat A, Stubbs D, Dunmore C, Ulliac N, Sexton B, Zieleniuk I, et al: Lack of interaction between two antihistamines, mizolastine and cetirizine, and ethanol in psychomotor and driving performance in healthy subjects. Eur J Clin Pharmacol 1995;48(2):143-150.
19. O'Hanlon JF, Ramaekers JG: Antihistamine effects on actual driving performance in a standard test: a summary of Dutch experience 1989-94. Allergy 1995;50(3):234-242.
20. Bonifazi F, Provinciali L, Antonicelli L, Bilo MB, Pucci S, Signorino M, et al: Comparative study of terfenadine and cetirizine in hay fever: assessment of efficacy and central nervous system effects. J Investig Allergol Clin Immunol 1995;5(1):40-46.
21. Shamsi Z, Kimber S, Hindmarch I: An investigation into the effects of cetirizine on cognitive function and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 2001;56(12):865-871.
22. Vermeeren A, Ramaekers JG, O'Hanlon JF: Effects of emedastine and cetirizine, alone and with alcohol, on actual driving of males and females. J Psychopharmacol 2002;16(1):57-64.
23. Hindmarch, Johnson S, Meadows R, Kirkpatrick T, Shamsi Z: The acute and sub-chronic effects of levocetirizine, cetirizine, loratadine, promethazine and placebo on cognitive function, psychomotor performance, and wheal and flare. Curr Med Res Opin 2001;17(4):241-255.
24. Weiler JM, Bloomfield JR, Woodworth GG, Grant AR, Layton TA, Brown TL, et al: Effects of fexofenadine, diphenhydramine, and alcohol on driving performance: a randomized, placebo-controlled trial in the Iowa driving simulator. Ann Intern Med 2000;132(5):354-363.
25. Vermeeren A, O'Hanlon JF: Fexofenadine's effects, alone and with alcohol, on actual driving and psychomotor performance. J Allergy Clin Immunol 1998;101(3):306-311.
26. Hindmarch I, Shamsi Z, Stanley N, Fairweather DB: A double-blind, placebo-controlled investigation of the effects of fexofenadine, loratadine and promethazine on cognitive and psychomotor function. Br J Clin Pharmacol 1999;48(2):200-206.
27. Mason J, Reynolds R, Rao N: The systemic safety of fexofenadine. Clin Exp Allergy 1999;29(Suppl. 3):163-170; discussion 171-173.
28. Simpson K, Jarvis B: Fexofenadine: a review of its use in the management of seasonal allergic rhinitis and chronic idiopathic urticaria. Drugs 2000;59(2):301-321.
29. Shamsi Z, Hindmarch I: Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios. Hum Psychopharmacol 2000;15(Suppl. 1):S3-S30.
30. Hindmarch I, Shamsi Z: Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects. Clin Exp Allergy 1999;29(Suppl. 3):133-142.
31. Raemakers JG, Vermeeren A: All antihistamines cross blood-brain barrier. Br Med J 2000;321:572.
32. Yanai K, Ryu JH, Watanabe T, Iwata R, Ido T, Sawai Y, et al: Histamine H1 receptor occupancy in human brains after single oral doses of histamine H1 antagonists measured by positron emission tomography. Br J Pharmacol 1995;116:1649-1655.
33. Yanai K, Okamura N, Tagawa M, Itoh M, Watanabe T: New findings in pharmacological effects induced by antihistamines: from PET studies to knock-out mice. Clin Exp Allergy 1999;29(Suppl. 3):29-36.
34. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, et al: Neuroimaging of histamine H1-receptor occupancy in human brain by positron emission tomography (PET): a comparative study of ebastine, a second-generation antihistamine, and (+)-chlorpheniramine, a classical antihistamine. Br J Clin Pharmacol 2001;52(5): 501-509.
35. Okamura N, Yanai K, Higuchi M, Sakai J, Iwata R, Ido T, et al: Functional neuroimaging of cognition impaired by a classical antihistamine, d-chlorpheniramine. Br J Pharmacol 2000;129:115-123.
36. 11C-doxepin PET study. J Nucl Med 2001;42:143P-144P.
37. Gardner SF, Green JA, Bednarczyk EM, Nelson AD, Leisure G, Miraldi F: An assessment of cerebral blood flow and metabolism after fleroxacin therapy. J Clin Pharmacol 1991;31(2):151-157.
38. Fowler JS, Volkow ND, Ding YS, Wang GJ, Dewey S, Fischman MW, et al: Positron emission tomography studies of dopamine-enhancing drugs. J Clin Pharmacol 1999;39(Suppl.):13S-16S.
39. Offord SJ, Wong DF, Nyberg S: The role of positron emission tomography in the drug development of M100907, a putative antipsychotic with a novel mechanism of action. J Clin Pharmacol 1999;39(Suppl.):17S-24S.
40. Cherry SR: Fundamentals of positron emission tomography and applications in preclinical drug development. J Clin Pharmacol 2001;41(5):482-491.
41. Mochizuki H, Tashiro M, Tagawa M, Kano M, Itoh M, Okamura N, et al: The effects of a sedative antihistamine, d-chlorpheniramine, on visuomotor spatial discrimination and regional brain activity as measured by positron emission tomography (PET). Hum Psychopharmacol 2002;17(8):413-418.
42. Holgate ST, Canonica GW, Simons FER, Taglialatela M, Tharp M, Timmerman H, et al: Consensus group on new generation antihistamines (CONGA): present status and recommendations. Clin Exp Allergy; in press.
43. Tagawa M, Kano M, Okamura N, Higuchi M, Matsuda M, Mizuki Y, et al: Differential cognitive effects of ebastine and d-chlorpheniramine in healthy subjects: correlation between cognitive impairment and plasma drug concentration. Br J Clin Pharmacol 2002;53:296-304.
44. Hoddes E, Zarcone V, Smythe H, Phillips R, Dement WC: Quantification of sleepiness: a new approach. Psychophysiology 1973;10:431-436.
45. 11C labelled radiopharmaceuticals from external measurement with thermoluminescent dosimeters. Phys Med Biol 1998;43:389-405.
46. Spinks TJ, Guzzardi R, Bellina CR: Performance characteristics of a whole body positron tomograph. J Nucl Med 1988;29:1833-1841.
47. Fujiwara T, Watanuki S, Yamamoto S, Miyake M, Seo S, Itoh M, et al: Performance evaluation of a large axial field-of-view PET scanner: SET-2400W. Ann Nucl Med 1997;11:307-313.
48. 11C]doxepin. J Labelled Comp Radiopharm 2002;45:271-280.
49. Sutherland FC, de Jager AD, Badenhorst D, Scanes T, Hundt HK, Swart KJ, et al: Sensitive liquid chromatography-tandem mass spectrometry method for the determination of loratadine and its major active metabolite descarboethoxyloratadine in human plasma. J Chromatogr A 2001;914(1-2):37-43.
50. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb Blood Flow Metab 1990;10:740-747.
51. 11C]doxepin and positron emission tomography. Neurosci Lett 1992;137:145-148.
52. Holland B, Copenhaver MD: An improved sequentially rejective Bonferroni test procedure. Biometrics 1987;43:417-423.